List of Excipients in Branded Drug ANJESO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baudax Bio Inc	ANJESO	meloxicam	71518-001	POVIDONE K12
Baudax Bio Inc	ANJESO	meloxicam	71518-001	SODIUM DESOXYCHOLATE

ANJESO Excipient Strategy and Commercial Opportunities for Intravenous Meloxicam

Last updated: September 24, 2026

ANJESO is an intravenous meloxicam product approved for the management of moderate-to-severe acute pain in adults. Its commercial differentiation depends less on the active ingredient than on formulation execution: aqueous solubilization, injection-site tolerability, ready-to-use hospital handling, and evidence supporting opioid-sparing use. The most attractive opportunities are follow-on injectable products, improved presentations, hospital-system contracting, and formulation-linked intellectual property.

What is ANJESO and how is it formulated?

ANJESO contains meloxicam, a preferential cyclooxygenase-2 inhibitor in the oxicam class. The product is supplied as a 30 mg/mL intravenous solution in single-dose vials. The FDA-approved dosing regimen is once daily, with a lower 15 mg dose recommended for certain patients, including adults weighing less than 60 kg and patients with increased adverse-event risk under the prescribing information. It is indicated for adults with moderate-to-severe acute pain, not for chronic pain treatment. (FDA, 2020a)

What excipients are used in ANJESO?

The FDA prescribing information identifies the following inactive ingredients:

Component	Likely formulation role
Povidone	Solubilization support, viscosity control, and stabilization
Sodium hydroxide	pH adjustment and meloxicam ionization control
Hydrochloric acid	pH adjustment
Water for Injection	Aqueous vehicle

ANJESO is a high-concentration aqueous injection. The formulation strategy relies on pH control and excipient-assisted solubilization rather than a conventional oral-tablet excipient system. The product is preservative-free and supplied in single-dose containers, which aligns with hospital injection practices and reduces concerns associated with multidose antimicrobial preservatives. (FDA, 2020a)

Why is excipient selection commercially important?

Meloxicam has limited aqueous solubility. An injectable formulation therefore must maintain the drug in solution through manufacturing, storage, dilution, and administration. The excipient system must also support:

• Chemical stability over the labeled shelf life
• Low particulate formation
• Acceptable osmolality and pH
• Compatibility with intravenous administration
• Tolerability at the injection site
• Reproducible vial filling at high drug concentration
• Compatibility with common hospital infusion materials

The central technical challenge is balancing solubility against tolerability. A formulation that depends on extreme pH, high cosolvent loading, or aggressive surfactant levels may achieve concentration targets but create regulatory and commercial disadvantages.

What excipient strategy does ANJESO use?

ANJESO uses a relatively simple excipient platform based on povidone, pH modifiers, and water for injection. This strategy has four commercial advantages.

First, it limits the number of novel excipient variables that must be characterized. Povidone is widely used in pharmaceutical products, including parenteral formulations, although its grade, molecular-weight distribution, impurity profile, and concentration remain important quality attributes.

Second, the formulation avoids the need for a complex lipid vehicle or a proprietary delivery device. That reduces manufacturing complexity and makes the product suitable for conventional sterile-liquid production.

Third, a preservative-free single-dose vial is compatible with hospital pharmacy workflows. It avoids the need to justify repeated-entry multidose handling.

Fourth, the formulation can support a high drug concentration in a small fill volume. A 30 mg/mL presentation allows the standard 30 mg adult dose to be delivered from a 1 mL vial, which can reduce preparation volume and storage space.

What are the main formulation risks?

The primary technical risks are precipitation, pH drift, container interaction, and particulate generation.

Meloxicam precipitation can occur if the product is diluted into an incompatible solution, exposed to temperature excursions, or mixed with drugs that alter pH or ionic strength. A commercial follow-on product would need robust compatibility data covering common infusion fluids, syringes, needles, administration sets, and hospital storage conditions.

Povidone can introduce risks related to peroxide impurities, molecular-weight distribution, and interaction with packaging materials. These risks are manageable but must be controlled through excipient specifications and stability studies.

The formulation’s pH is also commercially important. Highly alkaline or acidic injections can increase pain, phlebitis, or local tissue irritation. Any attempt to increase meloxicam concentration through pH adjustment would need to demonstrate that the change does not worsen tolerability.

What commercial opportunities exist for ANJESO excipients?

The strongest opportunities are not limited to copying the existing formulation. They include new presentations that improve administration economics or reduce hospital preparation steps.

Ready-to-use and prefilled presentations

A prefilled syringe could reduce dose preparation time, pharmacy compounding steps, and medication-error risk. A 1 mL prefilled syringe would be technically attractive for the 30 mg adult dose, but the product would require container-closure compatibility, extractables and leachables testing, syringe-device validation, and evidence that the formulation remains stable during contact with the syringe barrel and elastomer.

A prefilled format could also support emergency departments, ambulatory surgery centers, and perioperative settings where rapid administration is commercially valuable.

Dilution-ready presentations

A higher-volume, lower-concentration presentation could target institutions that prefer direct addition to infusion bags or administration through established protocols. This option would trade smaller vial size for potentially improved tolerability and simpler dilution behavior.

A commercial formulation could be positioned around validated compatibility with:

• 0.9% sodium chloride injection
• 5% dextrose injection
• Common polyolefin bags
• Standard polypropylene or cyclic olefin syringes
• Existing hospital infusion tubing

The value would come from reducing pharmacy uncertainty rather than merely changing the excipient list.

Alternative solubilization systems

Potential alternative systems include cyclodextrins, polyethylene glycol, ethanol, propylene glycol, surfactants, or different polymeric solubilizers. Each may increase formulation flexibility, but each also introduces regulatory and commercial tradeoffs.

Excipient approach	Potential benefit	Main barrier
Cyclodextrin complexation	Improved aqueous solubility	Renal safety, dose burden, cost, regulatory precedent
Polyethylene glycol or propylene glycol	Higher drug loading	Injection tolerability and excipient exposure
Surfactant system	Solubilization and physical stability	Hemolysis, hypersensitivity, and compatibility concerns
Alternative polymeric solubilizer	Potentially improved stability	New impurity and extractables profile
Lyophilized formulation	Longer stability or easier transport	Reconstitution time, manufacturing cost, and handling burden

For a follow-on product, the commercial case for a new excipient system must be stronger than simple formulation novelty. The company would need to show measurable advantages in stability, administration, cost, safety, or supply reliability.

Lower-volume concentrated products

A product more concentrated than 30 mg/mL could lower packaging and freight costs. It would also increase the risk of precipitation, local irritation, dosing errors, and incomplete transfer from the vial. This is more likely to be attractive for controlled hospital pharmacy use than for broad emergency-department deployment.

Pediatric and special-population opportunities

ANJESO is approved for adults. A lower-strength or more dilute presentation could support weight-based dosing research in pediatric or adolescent populations, but that would require new clinical and regulatory development. Excipient exposure becomes more significant at lower body weights, particularly for cosolvents, surfactants, and polymers.

A formulation designed for older adults, patients with renal impairment, or patients at high gastrointestinal-risk could support targeted positioning, but the underlying meloxicam safety profile would remain a central commercial limitation. The excipient strategy cannot remove NSAID-related renal, gastrointestinal, cardiovascular, or bleeding risks.

What patents protect ANJESO and its formulation?

ANJESO was approved through the FDA’s 505(b)(2) pathway, which permits reliance in part on previously established information while allowing differences in formulation, route, dosage, or clinical use to be supported with additional data. The 505(b)(2) pathway is commercially relevant because it can create a period of market protection without requiring a full new-drug application program. (FDA, 2020b)

Patent protection for an injectable meloxicam product may cover:

• The aqueous formulation
• Concentration and pH ranges
• Use of povidone or other solubilizers
• Intravenous administration
• Once-daily dosing
• Treatment of acute pain
• Opioid-sparing perioperative use
• Stability and packaging configurations

The Orange Book should be used to confirm the current patent listings, expiry dates, pediatric exclusivity, and any FDA-recognized regulatory exclusivity associated with ANJESO. Patent scope and expiry cannot be inferred solely from the approval date. A potential entrant would also need to review issued claims, terminal disclaimers, patent-term adjustment, patent-term extension, and any litigation or settlement history. (FDA, 2024)

Are biosimilars relevant to ANJESO?

No. ANJESO contains a chemically synthesized small-molecule active ingredient, meloxicam. Biosimilar rules under the Public Health Service Act do not apply. Competitive entry would generally involve an ANDA or a 505(b)(2) application, depending on the product’s formulation, route, labeling, and reliance strategy.

When does ANJESO lose exclusivity?

ANJESO’s regulatory exclusivity began with FDA approval on February 20, 2020. The product’s commercial protection is determined by the interaction of FDA exclusivity and listed patents, not by the approval date alone.

The principal scenarios are:

Entry route	Likely strategic position
ANDA	Possible for a sufficiently equivalent injectable product with the required pharmaceutical equivalence and bioequivalence showing
505(b)(2)	More flexible route for formulation, administration, or clinical-use differences
Compounded product	Limited and highly fact-specific; not a direct substitute for FDA-approved commercial entry
New meloxicam injectable	Could compete through differentiated concentration, packaging, or labeling

Paragraph IV certification would be the likely mechanism for challenging an unexpired Orange Book-listed patent in an ANDA. A Paragraph IV filing can trigger patent litigation and, if the relevant statutory conditions are met, a 30-month stay of approval. The first valid Paragraph IV filer may also pursue 180-day generic exclusivity, subject to forfeiture rules. (FDA, 2024)

What FDA regulatory barriers affect a generic or follow-on ANJESO product?

The main barriers are pharmaceutical equivalence, injectable quality, and formulation comparability.

A generic applicant would need to address:

• Same active ingredient and route of administration
• Equivalent strength and dosage form
• Sterility assurance
• Particulate limits
• Bacterial endotoxin control
• Container-closure integrity
• Extractables and leachables
• Stability under labeled storage conditions
• In-use and dilution compatibility
• Injectable-device performance, if supplied in a prefilled format

A follow-on 505(b)(2) product could create a stronger commercial proposition by changing the presentation or excipient system, but it would likely require more clinical or bridging evidence. The tradeoff is between regulatory efficiency and meaningful product differentiation.

How strong is the commercial opportunity?

ANJESO’s commercial opportunity is concentrated in institutional acute-pain care. Potential customers include hospitals, ambulatory surgery centers, emergency departments, and surgical practices seeking non-opioid analgesic options.

The value proposition rests on four factors:

1. Intravenous delivery for patients unable to take oral medication.
2. Once-daily administration.
3. Potential use as part of multimodal analgesia.
4. A ready-to-use product that does not require oral absorption.

The opportunity is constrained by competition from intravenous acetaminophen, injectable NSAIDs, ketorolac, regional anesthesia, oral NSAIDs, and generic perioperative analgesics. Hospital pharmacy and therapeutics committees will compare acquisition cost, opioid reduction, length of stay, adverse events, nursing workload, and formulary restrictions.

ANJESO’s strongest commercial positioning is likely in protocols where injectable non-opioid analgesia is needed and ketorolac or intravenous acetaminophen is unsuitable, insufficient, or operationally less attractive. Promotional claims must remain consistent with the FDA-approved label and supporting clinical evidence.

How does ANJESO compare with competing injectable analgesics?

Product category	Main advantage	Excipient or commercial limitation
ANJESO	Once-daily IV meloxicam and NSAID-based analgesia	NSAID class risks; high acquisition-cost pressure
Ketorolac injection	Established hospital use and generic availability	More frequent dosing and renal, gastrointestinal, and bleeding concerns
IV acetaminophen	Broad hospital familiarity and non-NSAID mechanism	Dose limits, liver-related concerns, and generic competition
Opioid injection	Rapid analgesia and broad clinical familiarity	Respiratory depression, sedation, constipation, and dependence risks
Oral NSAID	Low cost and established use	Not suitable when oral administration is unavailable

ANJESO’s formulation advantage is operational rather than mechanistic. Its commercial case depends on how the product fits hospital workflows and multimodal pain protocols.

What manufacturing and IP barriers matter most?

The most defensible formulation IP would cover a narrow combination of concentration, pH, excipient ratio, stability profile, and administration conditions. Broad claims to “injectable meloxicam” are more vulnerable to prior-art challenges because meloxicam and parenteral NSAID formulations have been extensively studied.

Manufacturing barriers may still create practical protection. These include:

• Consistent high-concentration sterile filling
• Control of meloxicam precipitation
• Low particulate generation
• Povidone impurity control
• Container compatibility
• Stable supply of qualified parenteral-grade excipients
• Validated sterilization and aseptic processing
• Scalable vial or syringe filling

A company that controls a reproducible manufacturing process may maintain an economic advantage even when patent claims are narrow.

What licensing opportunities exist around ANJESO?

Potential licensing targets include:

• Regional rights for injectable meloxicam
• Hospital-focused commercialization rights
• Prefilled-syringe technology
• Sterile liquid manufacturing capacity
• Excipient and solubilization platforms
• Drug-device combination products
• Co-development of perioperative analgesia protocols

The most attractive deal structure would likely combine formulation rights with manufacturing and commercialization capabilities. A license limited to the active ingredient would offer less differentiation because meloxicam is widely available and generic oral products are established.

Key Takeaways

• ANJESO is a 30 mg/mL preservative-free intravenous meloxicam solution approved in 2020 for moderate-to-severe acute pain in adults.
• Its excipient strategy uses povidone, pH modifiers, and water for injection to support a high-concentration aqueous product.
• The strongest formulation opportunities are prefilled syringes, dilution-ready presentations, improved compatibility, and potentially lower-volume or alternative-stability products.
• Biosimilar competition is irrelevant because meloxicam is a small-molecule drug.
• Generic and follow-on competition would likely proceed through an ANDA or 505(b)(2) application.
• Patent risk depends on current Orange Book listings, issued claims, expiry calculations, and any Paragraph IV litigation.
• Commercial success depends on hospital formulary economics, opioid-sparing evidence, administration convenience, and manufacturing reliability.
• The most valuable formulation IP would combine excipient composition with concentration, pH, stability, packaging, and administration claims.

FAQs

Can ANJESO be reformulated with cyclodextrin?

Yes, a cyclodextrin-based formulation is technically possible, but it would require a new assessment of renal exposure, tolerability, stability, excipient burden, and regulatory requirements. It would be commercially justified only if it improves concentration, stability, or administration performance.

Is a prefilled ANJESO syringe likely to be patentable?

Potentially. Patentability would depend on the claimed combination of formulation, syringe materials, dose volume, stability, and administration method. A generic prefilled presentation without a technically meaningful distinction may face obviousness and anticipation challenges.

Can ANJESO be diluted before intravenous administration?

Dilution should follow the FDA-approved labeling and validated compatibility information. A competing product could create value by generating broader, clearly supported compatibility data for commonly used infusion fluids and administration systems.

Would a lower-dose ANJESO product expand the market?

It could expand use in patients requiring dose reduction, but the opportunity would depend on clinical evidence, labeling, dosing accuracy, and the economics of manufacturing a separate strength or presentation.

What is the main commercial weakness of ANJESO?

The principal weakness is competition from lower-cost generic injectable analgesics and established multimodal pain regimens. Excipient improvements can reduce operational friction, but they do not eliminate NSAID class warnings or hospital budget pressure.

References

1. U.S. Food and Drug Administration. (2020a). ANJESO (meloxicam) injection, for intravenous use: Prescribing information. Baudax Bio, Inc.

2. U.S. Food and Drug Administration. (2020b). Approval package for NDA 210583: ANJESO (meloxicam) injection. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services.